Aims & Scope

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development.

The journal has a strong scientific and medical focus, but also strives to serve a broader readership.

The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.

Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseases Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals Manufacturing Clinical studies Regulatory review of antibody therapeutics Post-approval topics, e.g., pricing, reimbursement and markets Patents Emerging markets for antibody therapeutics, including China and India All submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees.

View Aims & Scope

Metrics & Ranking

Impact Factor

Year Value
2025 7.3
2024 5.60

Journal Rank

Year Value
2024 855

Journal Citation Indicator

Year Value
2024 1956

SJR (SCImago Journal Rank)

Year Value
2024 2.699

Quartile

Year Value
2024 Q1

h-index

Year Value
2024 111

Impact Factor Trend


Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.


Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.


Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.


Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.


Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.


APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 6,110.00 AUD. Learn more.

Explore journals without APCs for alternative publishing options.


Quick Facts

Current Factor
7.3
First Published: 2025

SJR (SCImago Journal Rank)

SJR
2.699
First Published: 2024

Quartile

Current Quartile
Q1
First Published: 2024

Similar Journals

Top Journals in Related Fields